CClinicalTrials.gg
WithdrawnNCT01067677RETCHESUpdated Nov 14, 2017

Rescue Emetic Therapy for Children Having Elective Surgery

An interventional study of Metaclopramide and Ondansetron in Post Operative Nausea and Vomiting and Rescue Emetic Therapy, sponsored by Franklyn Cladis. Withdrawn at 1 site in United States. Open to participants aged 3 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2017-11-14.

Sponsored by Franklyn Cladis · Not applicable, Interventional, and Treatment

Why this study was withdrawn
We do not have the funding or resources to complete the study at this time
Phase
Not applicable
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
3 Years to 18 Years
Sex
All
01

Study summary

To compare ondansetron, metoclopramide, diphenhydramine, and placebo in order to determine which anti-emetic is most efficacious as a "rescue therapy" for pediatric patients ages 3-18 who have post-operative vomiting after a standardized prophylactic regimen of ondansetron and dexamethasone. We hypothesize that anti-emetics with a different mechanism of action than the prophylactic regimen will be the most effective "rescue therapy" in children having surgery in an ambulatory surgery center.

  1. Problem: Despite commonly-used anti-emetics for prophylaxis, some children still go on to develop post-operative vomiting (POV).

    Goal: To determine which anti-emetic--ondansetron, metoclopramide, diphenhydramine, or placebo--is most efficacious for pediatric patients in this situation.

  2. Hypothesis: Anti-emetic medications that have a different mechanism of action than the prophylactic regimen will be the most efficacious "rescue therapy."
  3. Hypothesis: Metoclopramide at the dose of 0.5 mg/kg (max dose 20 mg) will be more effective than ondansetron, diphenhydramine, or placebo as "rescue therapy."
02

Conditions studied

  • Post Operative Nausea and Vomiting
  • Rescue Emetic Therapy

Keywords

  • PONV
  • Post operative nausea and vomiting
  • rescue emetic therapy
03

In context

Nausea

822 studies on the registry are indexed under Nausea; 104 are open to participants now.

Browse Nausea studies →

Lead sponsor

This is the only study on the registry with Franklyn Cladis as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  1. Pediatric patients 3-17 years old
  2. Patients scheduled for tonsillectomy and/or adenoidectomy (with and without myringotomy) , or dental restoration,
  3. Patients receiving a general anesthetic (inhaled agent without nitrous oxide) with POV prophylaxis with two agents (ondansetron and dexamethasone)
  4. Post operative vomiting in PACU or second stage recovery requiring antiemetic rescue.

Exclusion criteria

Exclusion Criteria:

  1. Vomiting in the past 24 hours or antiemetics in previous 24 hours
  2. Allergy or sensitivity to ondansetron, dexamethasone, metoclopramide, or diphenhydramine
  3. Patients with diabetes
  4. Patients with seizures
  5. Patients receiving a benzodiazepine premedication
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Metoclopramide

    rescue emetic therapy

    Drug: Metaclopramide

  • Experimental
    Ondansetron

    Rescue emetic therapy

    Drug: Ondansetron

  • Experimental
    Diphenhydramine

    Rescue emetic therapy

    Drug: diphenhydramine

  • Placebo comparator
    Saline

    Placebo

    Drug: Saline

Interventions

  • DrugMetaclopramide

    0.5 mg/kg for rescue after PONV

  • DrugOndansetron

    0.1 mg/kg (max 4 mg0

  • Drugdiphenhydramine

    0.25 mg/kg (max 25 mg)

  • DrugSaline

    equal volume (5 ml)as experimental rescue medications

06

What researchers measure

Primary outcomes

  1. Primary-Incidence of POV after rescue antiemetic in PACU, car ride home, day of surgery, and POD #1 and 2

    Time frame: 48 hrs

Secondary outcomes

  1. Secondary - a. Discharge times

    Time frame: 48 hrs

  2. Adverse events (headaches, sedation, dystonic reaction, dry mouth)

    Time frame: 48 hrs

  3. POV risk factors. age, personal or family history of PONV, history of motion sickness, personal or family history of smoking

    Time frame: 48 hrs

07

Study locations

1 site
  • The Children's Hospital of Pittsburgh
    Pittsburgh, Pennsylvania 15210, United States
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 14, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01067677
Lead sponsor
Franklyn Cladis
Responsible party
Franklyn Cladis (Associate Professor, University of Pittsburgh) — Sponsor-investigator
First posted
Feb 11, 2010
Start date
Feb 2010
Primary completion
Feb 2012 (estimated)
Completion
Feb 2014 (estimated)
Last update
Nov 14, 2017

Study contacts

Franklyn P Cladis, MD
principal investigator · University of Pittsburgh

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion